Indivior PLC Ordinary Shares (INDV NASDAQ) stock market data APIs
$34.2911
1.34(3.9%)
as of February 4, 2026
Try our APIs with
free plan!
Indivior PLC Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Prev. Close
34.2911
Open
35.6361
High
35.8652
Low
34.2137
52 wk Range
7.62-38
Market Cap
4 293 M
P/E Ratio
36.1474
Shares Outstanding
125 M
Revenue
1 180 M
EPS
0.72
Beta
1.143
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Indivior PLC Ordinary Shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Indivior PLC Ordinary Shares data using free add-ons & libraries
Get Indivior PLC Ordinary Shares Fundamental Data
Indivior PLC Ordinary Shares Fundamental data includes:
- Net Revenue: 1 180 M
- EBITDA: 324 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 0.39
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Indivior PLC Ordinary Shares News
New
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
Sanofi SNY announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease. Th...
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Pacira BioSciences PCRX reported preliminary, unaudited total revenues of $196.9 million for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of $199 million. The investors were ...
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up to $500 million to accelerate the development of Teva’s anti-IL-15 antibo...
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
Last week, U.S. stock markets ended on a generally positive note, despite mid-week volatility. The tech-heavy Nasdaq Composite, the Dow Jones Industrial Average, and the S&P 500 have secured healthy g...
Get Indivior PLC Ordinary Shares fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
